NBIO — Nascent Biotech Cashflow Statement
0.000.00%
Last trade - 00:00- $0.14m
- $0.15m
Annual cashflow statement for Nascent Biotech, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4 | -0.959 | -0.47 | -2.8 | -2.09 |
| Non-Cash Items | 1.63 | 0.074 | -0.027 | 1.33 | 0.738 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.82 | -0.103 | 0.911 | -0.317 | 0.164 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -0.554 | -0.987 | 0.413 | -1.79 | -1.19 |
| Financing Cash Flow Items | — | — | — | 0.208 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.426 | 0.985 | -0.321 | 1.86 | 1.39 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.128 | -0.002 | 0.093 | 0.078 | 0.2 |